Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ. Arai H, et al. Among authors: umemoto k. Eur J Cancer. 2024 Apr;201:113914. doi: 10.1016/j.ejca.2024.113914. Epub 2024 Feb 10. Eur J Cancer. 2024. PMID: 38359495
Microsatellite instability: A 2024 update.
Yamamoto H, Watanabe Y, Arai H, Umemoto K, Tateishi K, Sunakawa Y. Yamamoto H, et al. Among authors: umemoto k. Cancer Sci. 2024 Jun;115(6):1738-1748. doi: 10.1111/cas.16160. Epub 2024 Mar 25. Cancer Sci. 2024. PMID: 38528657 Free PMC article. Review.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. Kim DW, et al. Among authors: umemoto k. Future Oncol. 2024;20(16):1057-1067. doi: 10.2217/fon-2023-0824. Epub 2024 Feb 13. Future Oncol. 2024. PMID: 38348690 Free PMC article.
Medication use and risk of reflux oesophagitis.
Ueta R, Komori S, Umemoto K, Hata M, Masuda E, Seto K, Nishiie Y, Suzuki K, Hisada Y, Yanai Y, Otake Y, Okubo H, Watanabe K, Akazawa N, Yokoi C, Akiyama J. Ueta R, et al. Among authors: umemoto k. BMJ Open Gastroenterol. 2024 Dec 16;11(1):e001468. doi: 10.1136/bmjgast-2024-001468. BMJ Open Gastroenterol. 2024. PMID: 39689936 Free PMC article.
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H; Japan Oncology Network in Hepatobiliary and Pancreas. Imaoka H, et al. Among authors: umemoto k. J Gastroenterol. 2024 Nov 30. doi: 10.1007/s00535-024-02186-9. Online ahead of print. J Gastroenterol. 2024. PMID: 39614927
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.
Sudo K, Nakamura Y, Ueno M, Furukawa M, Mizuno N, Kawamoto Y, Okano N, Umemoto K, Asagi A, Ozaka M, Ohtsubo K, Shimizu S, Matsuhashi N, Itoh S, Matsumoto T, Satoh T, Okuyama H, Goto M, Hasegawa H, Yamamoto Y, Odegaard JI, Bando H, Yoshino T, Ikeda M, Morizane C. Sudo K, et al. Among authors: umemoto k. Br J Cancer. 2024 Oct;131(7):1237-1245. doi: 10.1038/s41416-024-02834-0. Epub 2024 Aug 28. Br J Cancer. 2024. PMID: 39198618
206 results